ZIVO Bioscience (NASDAQ:ZIVO) Given Hold Rating at Maxim Group

ZIVO Bioscience (NASDAQ:ZIVOGet Free Report)‘s stock had its “hold” rating reiterated by equities research analysts at Maxim Group in a research report issued to clients and investors on Tuesday, Benzinga reports.

ZIVO Bioscience Price Performance

Shares of NASDAQ:ZIVO remained flat at $7.96 during trading on Tuesday. The stock had a trading volume of 86 shares, compared to its average volume of 977. The company has a market capitalization of $22.61 million, a PE ratio of -2.09 and a beta of 0.20. The stock has a 50 day simple moving average of $7.82 and a two-hundred day simple moving average of $6.15. ZIVO Bioscience has a 52 week low of $0.48 and a 52 week high of $17.82.

ZIVO Bioscience (NASDAQ:ZIVOGet Free Report) last issued its quarterly earnings data on Monday, May 13th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter. The company had revenue of $0.04 million during the quarter.

About ZIVO Bioscience

(Get Free Report)

ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.

Featured Articles

Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.